Picture of Elicera Therapeutics AB logo

ELIC Elicera Therapeutics AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Elicera Concludes Preclinical Proof-Of-Concept Studies For Elc-201

April 27 (Reuters) - Elicera Therapeutics AB  ELIC.ST :
    * ELICERA THERAPEUTICS SUCCESSFULLY CONCLUDES PRECLINICAL
PROOF-OF-CONCEPT STUDIES FOR ONCOLYTIC VIRUS ELC-201 CONFIRMING
THE PROPOSED MODE-OF-ACTION
    * STUDY RESULTS CONFIRM ELC-201'S PROPOSED MODE-OF-ACTION

Source text for Eikon:  ID:nWkr4PdyPd 
Further company coverage:  ELIC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))

Recent news on Elicera Therapeutics AB

See all news